iBio reports IBIO-600 NHP half-life up to 52 days; Activin E antibody shows 34% weight loss with semaglutide

iBio, Inc.

IBIO-600 NHP half-life 40-52 days; estimated human half-life up to 130 days, enabling once every 3-6 month dosing.
IBIO-600 promoted dose-dependent lean mass increase (3.1% low-dose, 5.1% high-dose) and fat reduction in NHPs after 8 weeks.
Activin E antibody monotherapy in obese mice: 4% weight loss, 18% total body fat reduction vs placebo after 2 weeks.
Activin E antibody combined with semaglutide: 34% total weight loss, 72% fat reduction – synergistic beyond GLP-1 alone.
iBio on track for IBIO-600 regulatory submission in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.